Formulary Chapter 2: Cardiovascular system - Full Chapter
|
02.12 |
Lipid-regulating drugs |
|
|
02.12 |
Bile acid sequestrants |
|
|
Rosuvastatin tabs
|
Restricted
|
Initiation on the recommendation of a Consultant in the Lipid Clinic, Diabetes Unit, HIV Unit or Cardiology only
Restricted to use for:
Familial hyperlipidaemia (FH), where other statins have failed to achieve a >50% fall in LDL cholesterol. These patients should be under the care of a lipid clinic
Second line for patients requiring ‘high intensity statin’ post ACS, with contraindications or drug interactions that prevent the use of high doses of atorvastatin
Third line for patients with CVD or diabetes requiring substantial falls in cholesterol to achieve the minimum QoF audit standard (total cholesterol <5mmol/L and LDL <3mmol/L) with previous failure to tolerate up titrated doses of / or max doses of atorvatatin, and where
pravastatin is unlikely to deliver the lipid lowering potency required to reach these target levels
|
02.12 |
Nicotinic acid group |
|
|
02.12 |
Omega-3 fatty acid compounds |
|
|
02.12 |
Other lipid modifying agents |
|
|
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |

|
Specialist or hospital prescribing only.
The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital.
In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.
|

|
Treatment can be initiated in primary care after a recommendation from an appropriate specialist |

|
Specialist initiation followed by maintenance prescribing in primary care |

|
Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation |

|
Specialist and non-specialist initiation |

|
Not recommended for prescribing |
|
|